We developed and obtained a patent for next generation PPI formulation called "Lansid capsule", which demonstrates superior stability and efficacy compared to the existing omeprazole formulations for the treatment of peptic ulcers and gastro esophageal reflux disease.

Multiple first generics have been approved and demonstrated equivalence through bioequivalence testing.
Topisopam, Terbinafine hydrochloride, Clarithromycin, Cefadroxil, Fluconazole, Ledipasvir, Glimepiride, Gabapentin Famciclovir, Zolpiclem Tartrate, Crofelemer Hydrochloride, and Lopinavir/Ritonavir have been commercialized by conducting formulated prescription drug research and bioequivalence testing.

We are currently researching new concept ARB (Angiotensin II receptor blocker) for hypertension treatment, various mechanisms for Parkinson's disease treatment, Antidepressants, asthma therapeutics, and topical antifungal agents with novel mechanisms of action.